Time to Reconsider Endologix, Inc. (ELGX) After Making 52-Week High?

June 14, 2018 - By Nellie Frank

Endologix, Inc. (NASDAQ:ELGX) Logo

Investors sentiment decreased to 0.86 in 2018 Q1. Its down 0.24, from 1.1 in 2017Q4. It dropped, as 12 investors sold Endologix, Inc. shares while 31 reduced holdings. 11 funds opened positions while 26 raised stakes. 81.20 million shares or 6.75% less from 87.08 million shares in 2017Q4 were reported.
Automobile Association holds 0% or 121,457 shares in its portfolio. Axa has 0.02% invested in Endologix, Inc. (NASDAQ:ELGX). Alliancebernstein L P reported 111,157 shares or 0% of all its holdings. Weiss Multi reported 0% in Endologix, Inc. (NASDAQ:ELGX). Partner Investment Management Lp holds 0.44% or 95,319 shares. Credit Suisse Ag has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Prelude Capital Mgmt Ltd Liability invested in 448 shares. Deutsche National Bank & Trust Ag, a Germany-based fund reported 124,729 shares. Jpmorgan Chase And has 0% invested in Endologix, Inc. (NASDAQ:ELGX) for 22,941 shares. D E Shaw & Incorporated holds 0.01% or 1.66 million shares in its portfolio. Schwab Charles Investment stated it has 380,648 shares or 0% of all its holdings. American Interest Group, a New York-based fund reported 52,569 shares. Employees Retirement Association Of Colorado has invested 0% in Endologix, Inc. (NASDAQ:ELGX). Swiss Bancorporation invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Bnp Paribas Arbitrage reported 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX).

Since May 29, 2018, it had 0 buys, and 1 insider sale for $91 activity.

The stock of Endologix, Inc. (NASDAQ:ELGX) hit a new 52-week high and has $7.07 target or 8.00 % above today’s $6.55 share price. The 6 months bullish chart indicates low risk for the $550.27 million company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $7.07 price target is reached, the company will be worth $44.02 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 2.34% or $0.15 during the last trading session, reaching $6.55. About 179,556 shares traded. Endologix, Inc. (NASDAQ:ELGX) has risen 18.20% since June 14, 2017 and is uptrending. It has outperformed by 5.63% the S&P500.

Analysts await Endologix, Inc. (NASDAQ:ELGX) to report earnings on August, 1. They expect $-0.19 EPS, down 90.00 % or $0.09 from last year’s $-0.1 per share. After $-0.16 actual EPS reported by Endologix, Inc. for the previous quarter, Wall Street now forecasts 18.75 % negative EPS growth.

Endologix, Inc. (NASDAQ:ELGX) Ratings Coverage

Among 4 analysts covering Endologix (NASDAQ:ELGX), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Endologix had 5 analyst reports since January 2, 2018 according to SRatingsIntel. The firm has “Underweight” rating given on Tuesday, January 2 by JP Morgan. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, February 22. The stock of Endologix, Inc. (NASDAQ:ELGX) earned “Hold” rating by Stifel Nicolaus on Monday, May 21.

Another recent and important Endologix, Inc. (NASDAQ:ELGX) news was published by Ocbj.com which published an article titled: “Midday Stock Roundup” on May 21, 2018.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $550.27 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

Endologix, Inc. (NASDAQ:ELGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: